Danish CEO starts crucial tests of contrast agent
![Magnus Corfitzen, CEO of Ascelia Pharma. | Foto: Ascelia Pharma/ PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11958913.ece/ALTERNATES/schema-16_9/doc79del17uo9f1e6ejv5sa.jpg)
Ascelia Pharma, which is based in Malmø and has Magnus Corfitzen as CEO, has started to treat its first patient with its key asset Mangoral, which is planned for launch in the USA and Europe in 2022.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Strong interest in Swedish biotech IPO
For abonnenter